Bilirubin Hematofluorometer Project Awarded Phase IIb Funding

Aviv Biomedical has been awarded a two year NIH Phase IIb SBIR grant (5R44TR001635-04 & 5R44TR001635-05) to make additional improvements, and prepare the Bilirubin Hematofluorometer for regulatory approval.  Aviv has already completed Phase I (proof-of-principle), and Phase II (successful commercialization) funding.  NIH SBIR Phase IIb funding is awarded to proven…

Continue reading